ANI Pharmaceuticals | ANIP - Sales Revenues


ANI Pharmaceuticals reported $227.81M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
ANI Pharmaceuticals USD 227.81M 16.44M Sep/2025
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Heron Therapeutics USD 32.81M 3.21M Sep/2024
Hikma Pharmaceutical USD 829M 758M Jun/2025
Knight Therapeutics CAD 92.26M 3.31M Sep/2024
Nektar Therapeutics USD 24.12M 635K Sep/2024
Novartis USD 14.36B 478M Sep/2025
Perrigo USD 1.11B 70M Dec/2025
Sun Pharmaceuticals INR 147.99B 3.21B Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025